Genentech’s SMA Type 1 Data Strengthen Case Backing Risdiplam Approval

 
• By Joseph Haas
LabmicroscopeDNAgel_1200x675
Top-line data in type 1 SMA patients strengthens the case for risdiplam

More from Clinical Trials

More from R&D